Link Pharma Chem Ltd.

As of June 30, 2026, Link Pharma Chem Ltd. carries a market capitalization of 126.33M, placing it among publicly traded companies globally. Its enterprise value stands at 126.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Link Pharma Chem Ltd. has 4.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Link Pharma Chem Ltd. trades at an EV/EBITDA multiple of 10.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 52.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 126.33M versus a market cap of 126.33M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 3.42M in revenue per employee across its workforce of 83.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Link Pharma Chem Ltd. recorded 207,000.00 in income tax expense. That works out to an effective tax rate of 145.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 142,000.00, leaving -65,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Link Pharma Chem Ltd.'s stock has declined approximately 29.12% over the past 52 weeks. The 50-day moving average sits at 27.24, while the 200-day moving average is 27.83.

Over the twelve months ended June 30, 2026, Link Pharma Chem Ltd. generated 283.85M in revenue and converted that into -65,000.00 in net income, yielding earnings per share of -0.01. EBITDA reached 12.54M, while operating income came in at 2.39M.

Over the twelve months ended June 30, 2026, Link Pharma Chem Ltd. posted a gross margin of 58.46, reflecting its pricing power and cost economics. The operating margin of 0.84 and net profit margin of -0.02 provide insight into operational efficiency.